Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Aggravation of existing disorder; This is a spontaneous report from a contactable pharmacist downloaded from the Regulatory Authority-WEB, regulatory authority number FR-AFSSAPS-PB20215307. An 81-year-old male patient received the second dose of BNT162B2 (COMIRNATY, Lot number unknown) Intramuscular at single dose for COVID-19 immunisation on 04Aug2021. Relevant history included end stage COPD after smoking, ischemic heart disease, Multifactorial terminal respiratory failure (under O2 at home between 4 and 6l minutes), hypertension pulmonary, and fibrosis lung since May 2021, and post-lobectomy restriction. Relevant concomitant drug included paracetamol (DOLIPRANE) for pain. On 04Aug2021, in the morning, the patient was less well, more asthenic, more sleepy, but conscious, communicating, no sign of distress respiratory, respiratory rate 20. No sign of concern. The 2nd dose of Pfizer vaccine done at 11:45 am on 04Aug2021. Patient already on doliprane systematically for pain. No effect immediately after the vaccine. At 4.30 p.m, the patient had deterioration of his general condition. Afebrile 37. Cyanotic, gray complexion. Cool hands, no sweat, no marbling. Conscious and communicating patient. No signs of respiratory distress. Reassessed at 7 p.m. Patient always conscious. T = 37.8. Signs of shock. Pulse quick, fast, regular. Mottling+++. respiratory rate 32 without sign of distress, without indrawing. A few moans and sweats at the start of the night. Lightweight. Quiet night afterwards, patient not conscious. Death noted at 8:15 am on 05Aug2021. It is unknown if autopsy was done. No follow-up attempts are possible; no further information expected, information about lot/batch number cannot be obtained ; Reported Cause(s) of Death: Aggravation of existing disorder
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166